Lupin announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Mandideep Unit II facility, classifying the inspection as Voluntary Action Indicated. The inspection at the facility was carried out by the U.S. FDA between 26 November 2018 and 04 December 2018.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
